Literature DB >> 1502372

Structure and parameterization of pharmacokinetic models: their impact on model predictions.

T J Woodruff1, F Y Bois, D Auslander, R C Spear.   

Abstract

There has been an increasing interest in physiologically based pharmacokinetic (PBPK) models in the area of risk assessment. The use of these models raises two important issues: (1) How good are PBPK models for predicting experimental kinetic data? (2) How is the variability in the model output affected by the number of parameters and the structure of the model? To examine these issues, we compared a five-compartment PBPK model, a three-compartment PBPK model, and nonphysiological compartmental models of benzene pharmacokinetics. Monte Carlo simulations were used to take into account the variability of the parameters. The models were fitted to three sets of experimental data and a hypothetical experiment was simulated with each model to provide a uniform basis for comparison. Two main results are presented: (1) the difference is larger between the predictions of the same model fitted to different data sets than between the predictions of different models fitted to the dame data; and (2) the type of data used to fit the model has a larger effect on the variability of the predictions than the type of model and the number of parameters.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1502372     DOI: 10.1111/j.1539-6924.1992.tb00667.x

Source DB:  PubMed          Journal:  Risk Anal        ISSN: 0272-4332            Impact factor:   4.000


  7 in total

Review 1.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Bootstrapping for pharmacokinetic models: visualization of predictive and parameter uncertainty.

Authors:  C A Hunt; G H Givens; S Guzy
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

3.  Validation of a decision support system for use in drug development: pharmacokinetic data.

Authors:  S Guzy; C A Hunt
Journal:  Pharm Res       Date:  1997-10       Impact factor: 4.200

4.  Model parameter estimation and analysis: understanding parametric structure.

Authors:  H Li; K Watanabe; D Auslander; R C Spear
Journal:  Ann Biomed Eng       Date:  1994 Jan-Feb       Impact factor: 3.934

5.  Benzene toxicokinetics in humans: exposure of bone marrow to metabolites.

Authors:  K H Watanabe; F Y Bois; J M Daisey; D M Auslander; R C Spear
Journal:  Occup Environ Med       Date:  1994-06       Impact factor: 4.402

6.  Species-specific pharmacokinetics of styrene in rat and mouse.

Authors:  J G Filser; U Schwegler; G A Csanády; H Greim; P E Kreuzer; W Kessler
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

7.  Incremental lifetime cancer risks computed for benzo[a]pyrene and two tobacco-specific N-nitrosamines in mainstream cigarette smoke compared with lung cancer risks derived from epidemiologic data.

Authors:  Karen H Watanabe; Mirjana V Djordjevic; Steven D Stellman; Patricia L Toccalino; Donald F Austin; James F Pankow
Journal:  Regul Toxicol Pharmacol       Date:  2009-06-18       Impact factor: 3.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.